Pediatric Cancer and Blood Disorders Programs

The Aflac Cancer and Blood Disorders Center offers a wide array of services for children with cancer, bleeding and clotting disorders, and sickle cell disease.

Our resources are focused on four main approaches for fighting these diseases:

Our Programs

  • Blood and Marrow Transplant

      As one of the top pediatric BMT programs in the country, we provide care that is uniquely designed to accommodate the full spectrum of a child’s needs with expertise in both autologous and allogeneic transplants. 

      In addition to treating malignant diseases, we are also proficient in treating a variety of nonmalignant diseases through transplant, such as bone marrow failure syndromes, hemoglobinopathies, metabolic disorders, immune deficiencies and histiocytic/hemophagocytic disorders. 

      Our team is recognized as a national leader in transplanting patients with sickle cell disease—we have cured more than 45 children.

  • Cancer

      We have more than 20 physicians who are highly skilled and experienced in treating children and young adults with all forms of cancer—from the most common to those rarely seen outside of the top pediatric centers. Our cancer programs include:

      Brain and Spinal Cord Tumors—We have one of the largest pediatric brain tumor programs in the country, following more than 700 children and young adults with brain tumors each year. 

      Our program features advanced imaging and neurosurgery capabilities, such as magnetic resonance imaging (MRI); software and techniques; an intra-operative MRI (iMRI) system; positron emission tomography; (PET) scanning; Gamma Knife technology; and stereotactic radiosurgery and radiotherapy

      Leukemia and Lymphoma—Our program offers a large team of providers with specialized expertise in treating all forms of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma (NHL). 

      Each year, our program cares for approximately 125 newly diagnosed patients using a variety of treatment protocols, including BMT and Phase I and Phase II trials for patients whose cancer has relapsed or is not responding to treatment.

      Solid Tumor—Our program consists of medical and research professionals dedicated to treating solid tumors and developing new treatments and cures for the future. We care for approximately 125 newly diagnosed patients with these forms of cancer each year. 

      Additionally, our solid tumor program is one of the only programs in the Southeast offering therapeutic MIBG to patients with neuroblastoma.

  • Cancer Survivorship

      Since 2001, we have offered a multidisciplinary Cancer Survivorship Program to address the unique needs of childhood cancer survivors who are at least two years off therapy. Our program currently follows more than 1,500 childhood cancer survivors. 

      Additionally, our team developed SurvivorLink™—a revolutionary web-based tool for survivors and their care teams to access their electronic Survivor Healthcare Plan (SHP).

  • Hematology

      Bleeding and Clotting Disorders—In collaboration with Emory University School of Medicine, we follow more than 1,000 children and adults with bleeding disorders and approximately 200 with clotting disorders in our Comprehensive Hemostasis and Thrombosis Program. We treat a wide range of disorders, including hemophilia, thrombosis and von Willebrand disease.

      Sickle Cell Disease–Our Sickle Cell Disease Program—the largest pediatric program in the country, with more than 1,700 active patients—offers comprehensive clinics, transfusional services, specialty clinics and inpatient care. In addition, we have innovative services and technology to manage—and even cure—sickle cell disease, such as Transcranial Doppler (TCD) screening to evaluate patients for stroke risk and eligibility for BMT.

  • Innovative Therapy

      As one of the most active institutions in the U.S. in regards to pediatric clinical trial enrollment, we strive to improve and enhance the quality of life for children and young adults by offering some of the most promising new cancer agents and treatments for children who have relapsed or who have difficult-to-treat cancers through early-phase clinical trials.

      Additionally, we participate in a number of national collaborative research consortia geared toward the early clinical development of promising therapies for the treatment of cancer and blood disorders in children and young adults. Highlights include:

      - One of 21 centers in the country participating in COG Phase I and Pilot Consortium research

      - Among a small group of universities and children’s hospitals with access to Phase I and Phase II neuroblastoma clinical trials through New Approaches to Neuroblastoma Therapy (NANT)

      - One of 17 sites in the country participating in the NIH-funded Transfusion Medicine and Hemostasis Research Network

      - One of only eight centers in the country awarded funds to participate in the NIH Sickle Cell Clinical Research Network

      - A member of the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium, whose members work together to develop and carry out clinical trials

      - Among only a few pediatric centers in the country to offer MIBG therapy, a treatment option for patients with refractory or recurrent neuroblastoma and malignant pheochromocytoma

  • Fellowship

      We offer three-year pediatric Hematology/Oncology fellowships in collaboration with Emory University School of Medicine. Emory is among the largest pediatric hematology/oncology training programs in the country and the premiere program in the Southeast. 

      Our goal is to train academically oriented hematologists/oncologists who will be involved in a lifetime of excellence in pediatric patient care, teaching and clinical, translational or basic research. 

      Additionally, we offer a psychology fellowship program. This one-year training program is affiliated with the Emory University School of Medicine Postdoctoral Fellowship Training Program in Professional Psychology.

  •